Wall Street brokerages expect Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to announce earnings per share of ($0.18) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Keryx Biopharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.22). Keryx Biopharmaceuticals posted earnings per share of ($0.32) during the same quarter last year, which would suggest a positive year over year growth rate of 43.8%. The firm is scheduled to report its next earnings results on Wednesday, March 7th.

On average, analysts expect that Keryx Biopharmaceuticals will report full year earnings of ($1.36) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($1.35). For the next year, analysts expect that the business will post earnings of ($0.45) per share, with EPS estimates ranging from ($0.55) to ($0.32). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. The company had revenue of $15.00 million for the quarter, compared to analysts’ expectations of $18.88 million. During the same period in the prior year, the company posted ($0.39) EPS. The firm’s revenue was up 138.1% compared to the same quarter last year.

KERX has been the topic of several research reports. BidaskClub lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Zacks Investment Research lowered Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 8th. ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. Finally, Stifel Nicolaus reduced their price objective on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating for the company in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $7.35.

Keryx Biopharmaceuticals (NASDAQ:KERX) traded down $0.08 during trading hours on Tuesday, reaching $4.71. The company had a trading volume of 2,592,200 shares, compared to its average volume of 1,534,563. The company has a debt-to-equity ratio of 13.95, a quick ratio of 3.76 and a current ratio of 4.46. Keryx Biopharmaceuticals has a 52-week low of $4.47 and a 52-week high of $8.38.

Several institutional investors and hedge funds have recently modified their holdings of KERX. Fox Run Management L.L.C. purchased a new stake in Keryx Biopharmaceuticals in the 3rd quarter worth approximately $101,000. Engineers Gate Manager LP acquired a new position in shares of Keryx Biopharmaceuticals in the 3rd quarter valued at $102,000. Principal Financial Group Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 590 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Keryx Biopharmaceuticals by 51.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 5,628 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Keryx Biopharmaceuticals by 1.2% in the 1st quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 300 shares during the last quarter. 64.83% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/05/keryx-biopharmaceuticals-inc-kerx-expected-to-announce-earnings-of-0-18-per-share.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.